FDA Approves Strensiq™ (asfotase alfa) for Treatment of Patients with Perinatal-, Infantile- and Juvenile-Onset Hypophosphatasia (HPP)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Rescue work underway after quakes rock Venezuela, 'high casualties' likely
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
Baird Remains Bullish on Alexion Pharma (ALXN) as FDA Approves Strensiq
October 27, 2015 9:14 AM EDTBaird reiterated an Outperform rating and $221.00 price target on Alexion Pharmaceuticals (NASDAQ: ALXN) following Strensiq's FDA approval for hypophosphatasia. The company plans to use a sales force approximately double that at Soliris launch, to promote both Strensiq and Kanuma (PDUFA: December 8) along with Medical... More
FDA Approves Strensiq for Alexion Pharma (ALXN); Oppenheimer Reiterates Outperform
October 26, 2015 3:25 PM EDTOppenheimer reiterated an Outperform rating and $228.00 price target on Alexion Pharmaceuticals (NASDAQ: ALXN) following FDA's approval of Strensiq for treatment of perinatal, infantile, and juvenileonset hypophosphatasia. Alexion announced anticipation of a $285,000 average annual cost initially for Strensiq. However, as children grow and live beyond HPP natural history,... More
Alexion Pharma (ALXN) to Resume Trading at 4:15 PM ET
October 23, 2015 3:57 PM EDTAlexion Pharma (NASDAQ: ALXN) to Resume Trading at 4:15 PM ET
... More